X

Trial Profile

A Phase I, Double-blind, Randomized, Placebo-controlled, Single-dose, Dose-escalation Study of KRN23 in X-linked Hypophosphatemia

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 19 Jun 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Burosumab (Primary) ; Burosumab (Primary)
Indications Hyperphosphataemia
Focus Adverse reactions
Sponsors Kyowa Hakko Kirin; Kyowa Kirin

Most Recent Events

11 Oct 2013 New trial record
08 Oct 2013 Results presented at the 35th Annual Meeting of the American Society for Bone and Mineral Research.
07 Oct 2013 Results published in a Kyowa Hakko Kirin media release and presented at the American Society of Bone Mineralization Research (ASBMR) 2013 Annual Meeting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com